Veradigm (STU:AL21) EBIT per Share: €-0.78 (TTM As of Dec. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:AL21 Veradigm Inc STU:AL21
23 GF Score
Price €3.40
View Full Analysis

What is Veradigm EBIT per Share?

Veradigm STU:AL21 23 EBIT per Share is €-0.78 as of Dec. 2022. GuruFocus rates STU:AL21 with a GF Score™ of 23/100. Among 524 Healthcare Providers & Services companies, Veradigm ranks worse than 190839.5% on this metric.

Veradigm's EBIT per Share for the six months ended in Dec. 2022 was €-0.50. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2022 was €-0.78.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Veradigm's EBIT per Share or its related term are showing as below:

STU:AL21's 3-Year EBIT Growth Rate is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 11.95
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Veradigm's EBIT for the six months ended in Dec. 2022 was €-54.3 Mil.

Veradigm  (STU:AL21) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Veradigm EBIT per Share Related Terms

Veradigm EBIT per Share Historical Data

* Premium members only.

The historical data trend for Veradigm's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veradigm EBIT per Share Chart

Veradigm Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec24
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.29 0.11 1.09 -0.48 -0.78

Veradigm Semi-Annual Data
Dec03 Dec04 Dec05 Dec06 Dec07 May09 May10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec24
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.32 0.12 1.18 -0.50 -0.78
STU:AL21
23GF Score
Veradigm Inc STU:AL21
EBIT per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Veradigm EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Veradigm's EBIT per Share for the fiscal year that ended in Dec. 2022 is calculated as

EBIT per Share(A: Dec. 2022 )
=EBIT/Shares Outstanding (Diluted Average)
=-54.277/112.079
=-0.48

Veradigm's EBIT per Share for the quarter that ended in Dec. 2022 is calculated as

EBIT per Share(Q: Dec. 2022 )
=EBIT/Shares Outstanding (Diluted Average)
=-54.277/108.059
=-0.50

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2022 was €-0.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of €-0.78 mean?
Veradigm (STU:AL21) has a EBIT per Share of €-0.78 as of Dec. 2022. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Veradigm and its competitors. According to the industry distribution chart, Veradigm ranks #999999 out of 524 companies in the Healthcare Providers & Services industry.
Is Veradigm's EBIT per Share too high?
Veradigm's current EBIT per Share is €-0.78. Based on the distribution chart, Veradigm ranks #999999 out of 524 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Veradigm has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Veradigm's EBIT per Share compare to CTEV and EVH?
According to the Healthcare Providers & Services industry distribution chart, Veradigm ranks #999999 out of 524 companies for EBIT per Share. This places Veradigm in the lower half of its industry. The industry median EBIT per Share is 11.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Healthcare Providers & Services company?
The median EBIT per Share among Healthcare Providers & Services companies is 11.95, based on 524 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Veradigm and its competitors. For the Healthcare Providers & Services industry, the median EBIT per Share is 11.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Veradigm's current EBIT per Share is €-0.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veradigm stock overvalued right now?
Veradigm (STU:AL21) has a current EBIT per Share of €-0.78. The current EBIT per Share is €-0.78. Veradigm's overall GF Score™ is 23/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Veradigm (STU:AL21), the current EBIT per Share is €-0.78 as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Veradigm Business Description

Other Exchanges MDRX:USA
Address 222 Merchandise Mart Plaza, Suite 2024, Chicago, IL, USA, 60654
Veradigm Inc together with its subsidiaries, is a healthcare software-as-a-service (SaaS) technology, data and analytics company spanning the three pillars of healthcare: Provider, Payer and Life Science. Its Provider segment represents the source of revenue, followed by the Payer segment, with the Life Science segment contributing a comparatively smaller portion. Its portfolio addresses a range of healthcare industry needs, with the goal of transforming health insightfully, providing key healthcare stakeholders with data, insights and artificial intelligence (AI) enhanced solutions to help improve health outcomes and reduce costs.
23GF Score

Get the complete analysis for STU:AL21

EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.40
Price